AzTrials
AzTrials

Jaundice, NeonatalLEDlightT2NCT03569254

Effectiveness, Safety and Perceptions With the Use of One LED Blanket Device in the Ambulatory Treatment of Jaundice

A study testing Neomedlight Phototherapy Blanket and Ohmeda-Fiber Optic Phototherapy Blanket in people with Jaundice, Neonatal and Phototherapy, run by Nathalie Charpak at 1 site in Colombia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objective: to evaluate the effectiveness, safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy to which a LED light mesh has been incorporated(a blanket), comparing it with the Ohmeda BiliBlanket Plus®. Read more about this study

Who is it for?
Ages Up to 1 month
Conditions the study is for
Jaundice, Neonatal, Phototherapy
What is being tested?
Neomedlight Phototherapy Blanket and Ohmeda-Fiber Optic Phototherapy Blanket
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
64 participants
Where
1 siteColombia
Study dates
1 Mar 2016to 5 Oct 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 1 month
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Low Risk Hyperbilirubinemia requiring phototherapy according to the guidelines of the American Academy of Pediatrics and recommendations for management of premature infants under 35 weeks, adopted by the Kangaroo Mother Care Ambulatory Program.
  • Start of jaundice at a chronological age greater than 48 hours.
  • Bilirubin level ≤18 mg / dL
  • Knowledge of blood groups of mother and child.
  • Parents are required to sign informed consent where they agree to participate in the study.

Who cannot join

  • Parents without availability to stay in the Kangaroo Mother Care Program for at least 6 hours.
  • Extensive skin lesions due to burns or sloughing at the physical examination prior to entering the study.

Trial locations and contacts

1 site in 1 country.

Colombia1 site
  • Hospital Universitario San Ignacio

    Bogotá, 110231

Other trials in Colombia

About this study

Official title: Effectiveness, Safety and Perceptions With the Use of One LED Blanket Device in the Ambulatory Treatment of Neonatal Jaundice

Objective: to evaluate the effectiveness, safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy to which a LED light mesh has been incorporated(a blanket), comparing it with the Ohmeda BiliBlanket Plus®. Methods: randomized controlled clinical trial with preterm or low birth weight infants requiring phototherapy. The study protocol was evaluated and accepted by the San Ignacio Hospital and "Pontificia Universidad Javeriana" research committee. Informed consent was requested from parents and the authors declared no conflict of interest. Sample size and allocation: using the STATA 12 program, a sample size of 64 patients was calculated(5% losses), 32 for each group, with significance level of 0.05, power of 80% and difference in bilirubin decreasing of at least 0,1 mg/dl/h with standard deviation of 0.14 mg/dl/h. A computer program randomized the allocation to the intervention and the concealment of the assignment was through sealed opaque envelopes. Seric bilirubin levels were taken at the start and at the end of phototherapy. Controls were done every 2 hours with the Bilicheck spectrophotometer device. Axillary temperature was measured at the beginning of phototherapy, at 30 min, 60 min, and every 2 hours during intervention. Physical examination and recording of side effects related were performed. Parents and health personnel answered a survey on comfort and perceptions with the use of the devices at the end of phototherapy. Analysis: Comparison of means was made for the decrease of bilirubin levels and body temperatures and chi-square for incidence of side effects and results of the survey.

Read the detailed description

Background: Jaundice due to hyperbilirubinemia is the most common entity that requires medical management in neonates. About 50% of full-term newborns and 80% of premature infants develop jaundice. The effectiveness of phototherapy for neonatal jaundice depends on two factors: the spectrum of light emitted and the spectral irradiation of light. An ideal phototherapy device should have a broad light emission surface, in order to cover the maximum of the body surface in the horizontal plane, it should be durable, generate relatively little heat and provide a wavelength and light intensity (radiation) optimal (460-490nm and ≥ 30uw / cm2 / nm). The conventional phototherapy devices use fluorescent lamps that emit heat and require eye protectors, in addition to increasing water losses, which requires a permanent monitoring of vital functions and temperature. Its use imposes hospitalization and consequently mother-child separation, always traumatic. The most recent devices use light emitting diodes (LED light) as the light source. Objective: to evaluate the effectiveness, safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy to which a LED light mesh has been incorporated (one blanket), comparing it with the Ohmeda BiliBlanket Plus®, used at the Kangaroo Mother Care Program for intermittent ambulatory phototherapy. Methods: randomized controlled clinical trial with preterm or low birth weight infants that required phototherapy according to the guidelines of the American Academy of Pediatrics. The Protocol was evaluated and accepted by the "Hospital Universitario San Ignacio and Pontificia Universidad Javeriana research committee". Informed consent was requested from parents and the authors declared no conflict of interest. Sample size and allocation: using the STATA 12 program, a sample size of 64 patients was calculated, 32 for each group, with significance level of 0.05, power of 80% and difference in bilirubin decreasing of at least 0,1 mg/dl/h with standard deviation of 0.14 mg/dl/h and 5% of losses. A computer program randomized the allocation to the intervention and the concealment of the assignment was through sealed opaque envelopes. Seric bilirubin levels were taken at the start and at the end of phototherapy. Controls were done every 2 hours with bilicheck spectrophotometer device. Axillary temperature was measured at the beginning of phototherapy, at 30 min, 60 min, and every 2 hours during intervention. Physical examination, recording of side effects related, mortality and requirement of hospital treatment were performed. Parents and health personnel answered a survey on comfort and perceptions with the use of the devices at the end of phototherapy. Analysis: Comparison of means was made for the decrease of bilirubin levels and body temperatures and chi-square for incidence of side effects, hospitalization, mortality and results of the survey.

Being tested
Neomedlight Phototherapy Blanket, Ohmeda-Fiber Optic Phototherapy Blanket
Keywords
infant, newborn, devices, treatment, hyperbilirubinemia
Medical subject headings
Jaundice, Neonatal, Hyperbilirubinemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Neomedlight Phototherapy BlanketDevice

    The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.

  • Ohmeda-Fiber Optic Phototherapy BlanketDevice

    This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).

Study groups in NCT03569254
Study groupRoleWhat they receive
Neomedlight Phototherapy BlanketExperimentalPhototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period.
Receives: Device: Neomedlight Phototherapy Blanket
Ohmeda-Fiber Optic Phototherapy BlanketActive comparatorPhototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket
Receives: Device: Ohmeda-Fiber Optic Phototherapy Blanket

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bilirubin change rate in mg/dl/h

    Bilirubin lowering rate (initial seric bilirubin- final seric bilirubin/time of phototherapy).

    Measured: through study completion, an average of 6 hours

Secondary outcomes (9)
  1. Patient temperature during phototherapy

    Axillary temperatures at 30 min, 60 min, 1 hour, 2 hours, 4 hours and 6 hours of phototherapy.

    Measured: through study completion, an average of 6 hours

  2. Incidence of skin lesions related to phototherapy

    rash, burns, etc... related to phototherapy

    Measured: through study completion, an average of 6 hours

  3. Incidence of dehydration related to phototherapy

    Dehydration documented with physical examination and weight

    Measured: through study completion, an average of 6 hours

  4. Incidence of diarrhea related to phototherapy

    Documented diarrhea

    Measured: through study completion, an average of 6 hours

  5. Incidence of other side effects related to phototherapy

    Other effects recorded in clinic history related to phototherapy

    Measured: through study completion, an average of 6 hours

  6. Perceptions of parents with the use of devices

    Comfort with heat, humidity, breastfeeding, proximity and possibility of contact with the baby. The investigators did a validated survey at the end of treatment using a Likert scale(1-7): 1=uncomfortable. 7=comfortable. 4=indifferent

    Measured: At study completion, an average of 6 hours.

  7. Perceptions of the health team with the use of the devices

    Comfort cleaning and using the device and comfort with light, heat, humidity, and feeding and taking care of the baby. The investigators did a validated survey at the end of treatment using a Likert scale(1-7): 1=uncomfortable. 7=comfortable, 4=indifferent

    Measured: At study completion, an average of 6 hours.

  8. Hospitalization for hyperbilirubinemia

    Rate of hospitalization for hyperbilirubinemia

    Measured: Between beginning of treatment and 72 hours after

  9. Mortality

    Rate of mortality related to treatment

    Measured: Between beginning of treatment and 72 hours after

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jun 2018
  2. Study start1 Mar 2016
  3. Primary completion5 Oct 2017
  4. Study completion5 Oct 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Parallel assignment randomized controlled clinical trial with preterm or low birth weight infants who have low risk hyperbilirubinemia requiring phototherapy
Masking
None (open label)
Enrolment
64 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03569254
Sponsor's protocol ID
2015/187
Acronym
LEDlightT2
Status last verified
Jul 2018
First submitted
4 Jun 2018
Last updated
19 Jul 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Neomedlight Phototherapy Blanket and Ohmeda-Fiber Optic Phototherapy Blanket in people with Jaundice, Neonatal and Phototherapy, run by Nathalie Charpak at 1 site in Colombia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bilirubin change rate in mg/dl/h (time frame: through study completion, an average of 6 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in